By Kamal Choudhury March 26 (Reuters) - Wave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a ...

Wave Life Sciences (WVE) stock plunges as the company interim data from an early-stage trial for WVE-007, its RNA-based ...

Wave Life Sciences Ltd. WVE shares are tumbling on Thursday following the announcement of interim Phase 1 data from its ...

NEW YORK--(BUSINESS WIRE)--Builds Bio+, the premier life science membership organization that connects all segments of the life sciences ecosystem across major regional clusters, today announced the ...

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced ...

Wave Life Sciences (WVE) stock plunged 30% after INLIGHT Phase 1 obesity trial data revealed modest results, sparking ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Over the past 150 years, humanity has unleashed unimaginable energy by splitting ...

Understand the fundamentals that drive life. Do basic research that leads to medical breakthroughs and improvements in our world. Study the underlying chemistry of organisms and ecosystems. Help ...

Anthropic announced Claude for Life Sciences, an AI integration for researchers to advance scientific discovery. Claude for Life Sciences is built around Anthropic's existing AI models and supports ...

Achieve exceeded long-term safety study requirements and secured a manufacturing partnership, positioning for a potential 1H ...